Analysis of expression of MHC class I molecules and TAP genes in malignant human cell lines

Folia Histochemica et Cytobiologica

Volumn 45, Issue 3, 2007, Pages 205-214

  Kaczmarek, Mariusz ^a   Frydrychowicz, Magdalena ^a   Rubiś, Błazej ^a   Mizera Nyczak, Ewa ^a,b   Nieruchalska, Edyta ^a   Sikora, Jan ^a   Kaczmarek, Elzbieta ^a   Zeromski, Jan ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

Flow cytometry; Immunohistochemistry; MHC class I; Real time PCR; RT PCR; TAP1; TAP2

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; MESSENGER RNA; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS;

EID: 35548967959     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Tait BD. HLA class I expression on human cancer cells. Implications for effective immunotherapy. Human Immunol. 2000;61:158-165.
2. Matsui M, Ikeda M, Akatsuka T. High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. Biochem Biophis Res Com. 2001;280:1008-1014.
3. Powis SH, Mockridge I, Kelly A et al. Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex. Proc Nat Acad Sci. 1992;89:1463-1467.
4. Zeidler R, Eissner G, Meissner P et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood. 1997;90:2390-2397.
5. Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol. 2000;18:515-520.
6. Browning M, Petronzelli F, Bicknell D et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens. 1996;47:364-371.
7. Cromme FV, van Bommel PF, Walboomers JM et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer. 1994;69:1176-1181.
8. Dissemond J, Gotte P, Mors J et al. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003; 13:253-258.
9. Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res. 2000;60:5789-5796.
10. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890-3895.
11. Palmisano GL, Pistillo MP, Capanni P et al. Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immunol. 2001;62:133-139.
12. Vitale M, Pelusi G, Taroni B et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005;11:67-72.
13. Corrias MV, Occhino M, Croce M et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens. 2001;57:110-117.
14. Heike M, Schmitt U, Hohne A, Huber C, Meyer zum Buschenfelde KH. Impaired HLA-class-I stability in a sarcoma cell line which stimulates exclusively HLA-class-II-restricted autologous T cells. Int J Cancer. 1996;67:743-748.
15. Imanishi T, Kamigaki T, Nakamura T et al. Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon. Kobe J Med Sci. 2006;52:85-95.
16. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res. 2000;60:1927-1933.
17. Singal DP, Ye M, Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 1996;68:629-636.
18. Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984; 32:219-229.
19. Nieruchalska E, Strzelczyk R, Woźniak A, Zurawski J, Kaczmarek E, Salwa-Zurawska W. A quantitative analysis of the expression of α-smooth muscle actin in mesangioproloferative (GnMes) glomerulonephritis. Folia Morphol. 2003;62: 140-142.
20. Van der Velde-Zimmermann D, Roijers FM, Bouwens-Rombouts A et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol. 1996;149:759-764.
21. Grandea III AG, Lehner PJ, Cresswell P, Spies T. Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin. Immunogenetics. 1997;46:477-483.
22. Kamarashev J, Ferrone S, Seifert B et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001;95:23-28.
23. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265-272.
24. Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Ebstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol. 1995;25:1374-1384.
25. Sanda MG, Restifo NP, Walsh JC et al. Molecular characterisation of defective antigen processing in human prostate cancer. J Nat Canc Inst. 1995;87:280-285.
26. Seliger B, Hohne A, Knuth A et al. Analysis of the Major Histocompatibility Complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 1996; 56:1756-1760.
27. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998;58:737-742.
28. White CA, Thomson SA, Cooper L et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells. Int J Cancer 1998; 75:590-595.
29. Herzer K, Falk CS, Encke J et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol. 2003;77:8299-8309.
30. Miyagi T, Tatsumi T, Takehara T et al. Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J Gastroenterol Hepatol. 2003; 18:32-40.
31. Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol. 2005;66:1-12.
32. Soubeyran P, Mallo GV, Moucadel V, Dagorn JC, Iovanna JL. Overexpression of Cdx1 and Cdx2 homeogenes enhances expression of the HLA-1 in HT-29 cells. Mol Cell Biol Res Commun. 2000;3:271-276.
33. Mofidi R, Walsh R, Ridgway PF et al. Objective measurement of breast cancer oestrogen receptor status through digital image analysis. Eur J Surg Oncol. 2003;29:20-24.
34. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893-901.
35. Van Kaer L. Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens. 2002;60:1-9.
36. de la Salle H, Saulquin X, Mansour I et al. Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002;128:525-523.
37. Yang T, McNally BA, Ferrone S, Liu Y, Zheng P. A single-nucleotide deletion eads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem. 2003;278: 15291-15296.
38. Alm K, Gruhler A, Galocha B et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6:613-621.
39. Ahn K, Meyer TH, Uebel S et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 1996;15:3247-3255.
40. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Adenovirus E19 has two mechanisms for affecting class I MHC expression. J Immunol. 1999;162:5049-5052.
41. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J. 2001;20:387-396.
42. Chen WH, Ding J, Gong WD et al. The mechanism for up-regulation of HLA-I expression on HepG2 cells by HBV. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2004;20:74-77.
43. Wang JP, Wang PZ, Li J et al. Study on the mechanism of HLA-I-expressing regulation caused by the core region mutation of HBV adr subtype. Zhonghua Gan Zang Bing Za Zhi. 2007;15:24-27.
44. Seliger B, Hohne A, Knuth A et al. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res. 1996;2:1427-1433.
45. Chattedee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem. 1998;273:16177-16183.
46. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. How much longer will tumour cells fool the immune system? Immunol Today. 2000;21:70-72.
47. Kallfelz M, Jung D, Hilmes C et al. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. Int J Cancer. 1999;81:125-133.
48. Singal DP, Ye M, Bienzle D. Transfection of TAP 1 gene restores HLA class I expression in human small-cell lung carcinoma. Int J Cancer. 1998;75:112-116.
49. Kurte M, Lopez M, Aguirre A et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol. 2004;173:1731-1737.